Literature DB >> 24647577

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

S M Landau1, B A Thomas, L Thurfjell, M Schmidt, R Margolin, M Mintun, M Pontecorvo, S L Baker, W J Jagust.   

Abstract

PURPOSE: The increasing use of amyloid PET in Alzheimer's disease research and clinical trials has motivated efforts to standardize methodology. We compared retention of the (11)C radiotracer Pittsburgh Compound B (PiB) and that of two (18)F amyloid radiotracers (florbetapir and flutemetamol) using two study populations. We also examined the feasibility of converting between tracer-specific measures, using PiB as the common link between the two (18)F tracers.
METHODS: One group of 40 subjects underwent PiB and flutemetamol imaging sessions and a separate group of 32 subjects underwent PiB and florbetapir imaging sessions. We compared cortical and white matter retention for each (18)F tracer relative to that of PiB, as well as retention in several reference regions and image analysis methods. Correlations between tracer pairs were used to convert tracer-specific threshold values for amyloid positivity between tracers.
RESULTS: Cortical retention for each pair of tracers was strongly correlated regardless of reference region (PiB-flutemetamol, ρ = 0.84-0.99; PiB-florbetapir, ρ = 0.83-0.97) and analysis method (ρ = 0.90-0.99). Compared to PiB, flutemetamol had higher white matter retention, while florbetapir had lower cortical retention. Two previously established independent thresholds for amyloid positivity were highly consistent when values were converted between tracer pairs.
CONCLUSION: Despite differing white and grey matter retention characteristics, cortical retention for each (18)F tracer was highly correlated with that of PiB, enabling conversion of thresholds across tracer measurement scales with a high level of internal consistency. Standardization of analysis methods and measurement scales may facilitate the comparison of amyloid PET data obtained using different tracers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647577      PMCID: PMC4055504          DOI: 10.1007/s00259-014-2753-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

1.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

2.  PET imaging of amyloid deposition in patients with mild cognitive impairment.

Authors:  Anton Forsberg; Henry Engler; Ove Almkvist; Gunnar Blomquist; Göran Hagman; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Neurobiol Aging       Date:  2007-05-11       Impact factor: 4.673

3.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

4.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

5.  The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease.

Authors:  Benjamin A Thomas; Kjell Erlandsson; Marc Modat; Lennart Thurfjell; Rik Vandenberghe; Sebastien Ourselin; Brian F Hutton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-19       Impact factor: 9.236

6.  Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand.

Authors:  Zsolt Cselényi; Maria Eriksdotter Jönhagen; Anton Forsberg; Christer Halldin; Per Julin; Magnus Schou; Peter Johnström; Katarina Varnäs; Samuel Svensson; Lars Farde
Journal:  J Nucl Med       Date:  2012-02-09       Impact factor: 10.057

7.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

Authors:  Nelleke Tolboom; Maqsood Yaqub; Ronald Boellaard; Gert Luurtsema; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-22       Impact factor: 9.236

8.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

9.  Relationships between biomarkers in aging and dementia.

Authors:  W J Jagust; S M Landau; L M Shaw; J Q Trojanowski; R A Koeppe; E M Reiman; N L Foster; R C Petersen; M W Weiner; J C Price; C A Mathis
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

10.  Characterization of PiB binding to white matter in Alzheimer disease and other dementias.

Authors:  Michelle T Fodero-Tavoletti; Christopher C Rowe; Catriona A McLean; Laura Leone; Qiao-Xin Li; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Nucl Med       Date:  2009-01-21       Impact factor: 10.057

View more
  98 in total

1.  Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.

Authors:  Zsolt Cselényi; Lars Farde
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-15       Impact factor: 6.200

Review 2.  Future Directions in Imaging Neurodegeneration.

Authors:  Joseph C Masdeu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

3.  Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes.

Authors:  Jordi A Matías-Guiu; María Nieves Cabrera-Martín; Teresa Moreno-Ramos; María Valles-Salgado; Marta Fernandez-Matarrubia; José Luis Carreras; Jorge Matías-Guiu
Journal:  J Neurol       Date:  2015-04-11       Impact factor: 4.849

4.  Establishing Amyloid PET Imaging Biomarkers: Ongoing Efforts.

Authors:  S Minoshima
Journal:  AJNR Am J Neuroradiol       Date:  2015-05-21       Impact factor: 3.825

5.  Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice.

Authors:  Ugo Paolo Guerra; Flavio Mariano Nobili; Alessandro Padovani; Daniela Perani; Alberto Pupi; Sandro Sorbi; Marco Trabucchi
Journal:  Neurol Sci       Date:  2015-06       Impact factor: 3.307

6.  Cognitive dispersion is a sensitive marker for early neurodegenerative changes and functional decline in nondemented older adults.

Authors:  Katherine J Bangen; Alexandra J Weigand; Kelsey R Thomas; Lisa Delano-Wood; Lindsay R Clark; Joel Eppig; Madeleine L Werhane; Emily C Edmonds; Mark W Bondi
Journal:  Neuropsychology       Date:  2019-03-21       Impact factor: 3.295

7.  Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging.

Authors:  Ying-Hwey Nai; Shoichi Watanuki; Manabu Tashiro; Nobuyuki Okamura; Hiroshi Watabe
Journal:  Radiol Phys Technol       Date:  2018-10-16

8.  Amyloid burden accelerates white matter degradation in cognitively normal elderly individuals.

Authors:  Ashwati Vipin; Kwun Kei Ng; Fang Ji; Hee Youn Shim; Joseph K W Lim; Ofer Pasternak; Juan Helen Zhou
Journal:  Hum Brain Mapp       Date:  2019-01-03       Impact factor: 5.038

9.  Harnessing the Digital Exhaust: Incorporating wellness into the pharma model.

Authors:  Justin M Wright; Graham B Jones
Journal:  Digit Biomark       Date:  2018-04-11

10.  Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Authors:  Michael J Properzi; Rachel F Buckley; Jasmeer P Chhatwal; Michael C Donohue; Cristina Lois; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2018-11-17       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.